The lancet oncology
-
The lancet oncology · Jul 2022
Multicenter StudyCabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties, in combination with the PD-L1 inhibitor atezolizumab in metastatic castration-resistant prostate cancer. ⋯ Exelixis.
-
The lancet oncology · Jul 2022
Multicenter StudyMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study.
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. ⋯ Insightec and the National Cancer Institute.
-
The lancet oncology · Jul 2022
ReviewStreamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective.
In a multiday conference, a panel of Latin American experts in biological cancer therapies and health economics were provided with questions to address the barriers restricting access to biosimilars in Latin America, specifically for patients with breast cancer and colorectal cancer, for whom biosimilars can be a path forward to increasing access to care. During the conference, responses were discussed and edited until a consensus was achieved. ⋯ Recommendations were developed to improve the implementation of regulatory pathways and reliable procurement strategies that increase access to these therapies with adequate traceability and outcome measures; efforts from all involved stakeholders will be crucial. These recommendations can serve as a strategy for biosimilar adoption in other countries in a similar situation.
-
The lancet oncology · Jul 2022
Randomized Controlled TrialHigh incidence of severe pain is associated with low opioid availability in patients with advanced cancer: a nationwide questionnaire survey in Japan.
Opioid availability for the palliative care of patients with advanced cancer is increasing globally. However, opioid consumption in Japan is still extremely low compared with that in other countries. We investigated the current situation of pain control and opioid consumption in patients with advanced cancer in Japan. ⋯ This study was funded by the authors and by Shionogi (Osaka, Japan), Nippon Zoki Pharmaceutical (Osaka, Japan), and Heartfelt (Kumamoto, Japan).
-
The lancet oncology · Jul 2022
Multicenter StudyAberrant circulating tumour DNA methylations as biomarkers for early detection of pancreatic ductal adenocarcinoma: a retrospective study.
Pancreatic ductal adenocarcinoma is a cancer with high mortality and low survival, the early detection of which is hampered by the absence of specific symptoms until an advanced stage is reached. No reliable early screening tool for pancreatic ductal adenocarcinoma is currently available. Circulating tumour DNA (ctDNA) methylation has emerged as a promising new type of biomarker for blood-based early detection of multiple types of cancer. As a part of the PanSeerX study, which aims to discover robust ctDNA methylation markers for multicancer early screening, a customised pancreatic ductal adenocarcinoma-specific targeted methylation sequencing panel has been preliminarily developed and validated for its accuracy in classifying pancreatic ductal adenocarcinoma from retrospective clinical plasma samples. ⋯ The National Key Research and Development Project of China (grant 2019YFC1315904), the 234 Discipline Climbing Plan Project of the First Affiliated Hospital of Naval Military Medical University (grant 2019YXK033), and the Shanghai Science and Technology Committee.